Barclays PLC Raises Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Barclays PLC lifted its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 273.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,463 shares of the company’s stock after acquiring an additional 12,051 shares during the quarter. Barclays PLC owned about 0.06% of LENZ Therapeutics worth $391,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in LENZ. SG Americas Securities LLC acquired a new position in LENZ Therapeutics during the 3rd quarter worth approximately $107,000. Squarepoint Ops LLC acquired a new position in LENZ Therapeutics during the 2nd quarter worth $181,000. MetLife Investment Management LLC bought a new stake in LENZ Therapeutics in the third quarter valued at about $182,000. GSA Capital Partners LLP bought a new stake in shares of LENZ Therapeutics in the 3rd quarter valued at approximately $246,000. Finally, Jane Street Group LLC acquired a new position in LENZ Therapeutics in the third quarter worth $286,000. 54.32% of the stock is owned by hedge funds and other institutional investors.

LENZ Therapeutics Stock Up 0.6 %

LENZ stock opened at $28.46 on Friday. The firm’s 50-day simple moving average is $32.55 and its 200 day simple moving average is $25.89. LENZ Therapeutics, Inc. has a fifty-two week low of $14.42 and a fifty-two week high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same quarter last year, the business posted ($1.33) earnings per share. As a group, analysts forecast that LENZ Therapeutics, Inc. will post -2.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price target on shares of LENZ Therapeutics in a report on Thursday, November 7th. Raymond James began coverage on LENZ Therapeutics in a research note on Friday, September 27th. They issued an “outperform” rating and a $37.00 target price for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $35.40.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.